Ireland· IE-PA-EU/1/24/1874/002
Hympavzi 150 mg solution for injection in pre-filled pen
A antihemorrhagics product containing marstacimab, registered in Ireland by Pfizer Europe MA EEIG. The same ATC class is registered in 2 of our 19 countries.
Checked against HPRA (Ireland) on
Informational only — not a medical device.
Where it is registered
Marstacimab is registered in 2 of 19 countries.
Countries holding a registration under ATC B02 (antihemorrhagics), each read from that country’s own register.
- This record: Ireland, from HPRA (Ireland)
Marstacimab · ATC B02
2 / 19 countries
- Ireland
- Netherlands
The record
At a glance
HPRA (Ireland)- Active substance
- Marstacimab
- Manufacturer
- Pfizer Europe MA EEIG
- Country
- Ireland (IE)
- ATC code
- B02
- ATC class
- ANTIHEMORRHAGICS
- Reimbursed
- Not published by this register
- Source register
- HPRA (Ireland)
- Last checked
- July 13, 2026
Packs & prices · 1
- ie_pa_numberEU/1/24/1874/002
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Marstacimab in 13 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- NetherlandsHympavzi 150 mg oplossing voor injectie in een voorgevulde penPfizer Europe MA EEIG
- United StatesHYMPAVZIPfizer Laboratories Div Pfizer Inc
- CzechiaHYMPAVZIPfizer Europe MA EEIG, Bruxelles
- IcelandHympavziPfizer Europe MA EEIG*
- BelgiumHympavzi 150 mgPfizer Europe MA
- PolandHympavziPfizer Europe MA EEIG
- SwedenHympavzi 150 mg Injektionsvätska, lösning i förfylld injektionspennaPfizer Europe MA EEIG
- FinlandHympavziPfizer Europe MA EEIG
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Hympavzi
- Liechtenstein · Hympavzi
- Norway · Hympavzi
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of HPRA (Ireland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/c29b36cd-4fe8-4e4d-91be-3fefd709e32f GET /v1/drugs/c29b36cd-4fe8-4e4d-91be-3fefd709e32f?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Solution for injection in pre-filled pen",
"routes": [
"Subcutaneous use"
],
"source": "hpra",
"atc_all": [
"B02"
],
"strength": null,
"pa_number": "EU/1/24/1874/002",
"substances": [
"Marstacimab"
],
"legal_basis": "Full application (Article 8(3) of Directive No 2001/83/EC)",
"market_info": "Unknown",
"authorised_at": null,
"dispensing_status": "Product subject to prescription which may not be renewed (A)",
"registration_status": "AU",
"supply_legal_status": "Supply through pharmacies only",
"interchangeable_code": null
}See everything about marstacimab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.